{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:20:08Z","timestamp":1747178408268,"version":"3.40.5"},"reference-count":15,"publisher":"Informa UK Limited","issue":"12","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2022,12,2]]},"DOI":"10.1080\/13543784.2022.2160314","type":"journal-article","created":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T03:51:35Z","timestamp":1671249095000},"page":"1265-1267","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Psoriasis: talking points from recent clinical trials"],"prefix":"10.1080","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6739-0387","authenticated-orcid":false,"given":"Andrea","family":"Chiricozzi","sequence":"first","affiliation":[{"name":"UOC di Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy"},{"name":"Dermatologia, Dipartimento di Medicina e Chirurgia Traslazionale, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6163-6921","authenticated-orcid":false,"given":"Francesco","family":"Bellinato","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Romita","sequence":"additional","affiliation":[{"name":"Department of Biomedical Science and Human Oncology, Section of Dermatology, University of Bari, Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-9001","authenticated-orcid":false,"given":"Paolo","family":"Gisondi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,12,25]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121746"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.1002"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-eular.1377"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10775.x"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.037"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103629"},{"key":"cit0008","unstructured":"McCulloch T. FDA approves arcutis\u2019 zoryve (roflumilast) cream 0. 3% for the treatment of plaque psoriasis in individuals age 12 and older. Arcutis Biotherapeutics. Published July 29, 2022. cited 2022 Aug 22. Available from: https:\/\/www.arcutis.com\/fda-approves-arcutis-zoryve-roflumilast-cream-0-3-for-the-treatment-of-plaque-psoriasis-in-individuals-age-12-and-older\/"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2000073"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.25251\/skin.5.supp.42"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"cit0012","unstructured":"GlobeNewswire. AnaptysBio presents updated data from imsidolimab phase 2 GALLOP trial in generalized pustular psoriasis 2021 [cited 2022 Sep 12]. Available from: https:\/\/www.globenewswire.com\/news-release\/2021\/10\/02\/2307446\/0\/en\/AnaptysBioPresents-Updated-Data-From-Imsidolimab-Phase-2-GALLOPTrial-in-Generalized-Pustular-Psoriasis.html"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.06.313"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1702147"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1727439"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2022.2160314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T12:42:48Z","timestamp":1675168968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2022.2160314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,2]]}},"alternative-id":["10.1080\/13543784.2022.2160314"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2022.2160314","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"type":"print","value":"1354-3784"},{"type":"electronic","value":"1744-7658"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}